Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi.

Merli, F; Luminari, S; Ilariucci, F; Petrini, M; Visco, C; Ambrosetti, Achille; Stelitano, C; Caracciolo, F; Di Renzo, N; Angrilli, F; Carella, Am; Capodanno, I; Barbolini, E; Galimberti, S; Federico, M.

doi:10.1111/j.1365-2141.2011.08958.x

CATALOGO DEI PRODOTTI DELLA RICERCA

IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.

This study investigated the clinical activity and toxicity of R-HCVAD-AM [rituximab plus HyperCVAD (R-HCVAD) alternating with high-dose cytarabine and methotrexate (AM)] in patients with newly diagnosed Mantle Cell Lymphoma (MCL). Patients aged ≤70years with confirmed MCL received four alternating cycles each of R-HCVAD and AM. Patients who obtained a partial response proceeded to autologous stem cell transplant. Sixty-three patients were enrolled and 60 were fully eligible. Median age was 57years (22-66); 60%, 33% and 7% were classified at low (L)-, intermediate (I)- or high (H)-risk, respectively, according to the MCL International Prognostic Index (MIPI). Only 22 patients (37%) completed the four cycles and three patients died during therapy. Overall response and complete response rates were 83% and 72% respectively. After a median follow-up of 46months (range 1-72) the estimated 5-year overall survival (OS) and progression-free survival rates were 73% [95% confidence interval (CI) 59-83%], and 61% (95%CI 45-73%) respectively. MIPI maintained the prognostic value with an estimated 5-year OS of 89%, 80% and 24% for L, I, and H groups respectively (P<0·001). This multicentre study confirms that R-HCVAD-AM is an active regimen for the initial treatment of patients with MCL, but is associated with significant toxicity

Titolo:	Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi.
Autori:	Merli F Luminari S Ilariucci F Petrini M VISCO, Carlo AMBROSETTI, Achille Stelitano C Caracciolo F Di Renzo N Angrilli F Carella AM Capodanno I Barbolini E Galimberti S Federico M. mostra contributor esterni nascondi contributor esterni
Data di pubblicazione:	2012
Rivista:	BRITISH JOURNAL OF HAEMATOLOGY
Handle:	http://hdl.handle.net/11562/431445
Appare nelle tipologie:	01.01 Articolo in Rivista

File in questo prodotto:

File	Descrizione	Tipologia	Licenza
Merli_et_al-2012-British_Journal_of_Haematology-2.pdf		Pre-print	Accesso ristretto	Utenti riconosciuti Richiedi una copia

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11562/431445

Citazioni

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.